The idea that α7nAChR interaction with Aβ may counteract the effects of Aβ at early stages but participate in processes that lead to neuronal dysfunction and cognitive decline at later stages of disease is intriguing and suggests that efforts to modulate α7nAChR as a therapeutic strategy should take disease stage into account. The gene discussed is CHRNA7; the disease is Mental deterioration.